MAP7 and ovarian carcinoma: This supports the hypothesis that MAP7's nuclear presence, particularly its interaction with CBY1, contributes significantly to the modulation of the Wnt/β-catenin pathway and the development of cisplatin resistance in ovarian cancer cells.